艾滋病疫苗功效试验的失败：下一步该往何处走。
The Failure of AIDS Vaccine Efficacy Trials: Where to Go from Here.
机构信息
University of Miami, Miller School of Medicine, Miami, Florida, USA.
出版信息
J Virol. 2023 Mar 30;97(3):e0021123. doi: 10.1128/jvi.00211-23. Epub 2023 Mar 14.
Abstract
The seven AIDS vaccine efficacy trials have yielded extremely disappointing results at great expense. Greater stringency is needed for government support of AIDS vaccine efficacy trials.
摘要
这七个艾滋病疫苗功效试验花费巨大，但结果却令人极其失望。政府对艾滋病疫苗功效试验的支持需要更加严格。
相似文献
1
The Failure of AIDS Vaccine Efficacy Trials: Where to Go from Here.艾滋病疫苗功效试验的失败：下一步该往何处走。
J Virol. 2023 Mar 30;97(3):e0021123. doi: 10.1128/jvi.00211-23. Epub 2023 Mar 14.
2
HIV/AIDS: vaccines and alternate strategies for treatment and prevention.艾滋病毒/艾滋病：疫苗和治疗及预防的替代策略。
Ann N Y Acad Sci. 2010 Sep;1205 Suppl 1:E1-9. doi: 10.1111/j.1749-6632.2010.05759.x.
3
Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand.泰国北部高危人群参与艾滋病疫苗试验的意愿。
AIDS. 1995 Sep;9(9):1079-83. doi: 10.1097/00002030-199509000-00015.
4
Disappointing data scuttle plans for large-scale AIDS vaccine trial.令人失望的数据打乱了大规模艾滋病疫苗试验的计划。
Science. 2002 Mar 1;295(5560):1616-7. doi: 10.1126/science.295.5560.1616.
5
Thorny issues in the ethics of AIDS vaccine trials.艾滋病疫苗试验伦理中的棘手问题。
Lancet. 2003 Sep 20;362(9388):992. doi: 10.1016/S0140-6736(03)14371-1.
6
Development of prophylactic AIDS vaccines: the current state of affairs.预防性艾滋病疫苗的研发：现状
Curr Opin Mol Ther. 2003 Feb;5(1):25-32.
7
Thailand weighs AIDS vaccine tests.泰国权衡艾滋病疫苗测试。
Science. 1995 Nov 10;270(5238):904-7. doi: 10.1126/science.270.5238.904.
8
Replicating viral vectors as HIV vaccines: summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference.作为艾滋病疫苗的复制型病毒载体：2009年艾滋病疫苗会议上由国际艾滋病疫苗倡议组织主办的卫星研讨会总结报告
Biologicals. 2010 Jul;38(4):511-21. doi: 10.1016/j.biologicals.2010.03.005.
9
[HIV/AIDS vaccines: heading for new vaccine approaches?].[艾滋病疫苗：走向新的疫苗研发途径？]
Bull Soc Pathol Exot. 2008 Jun;101(3):220-6.
10
Vaccines for the control of HIV/AIDS.用于控制艾滋病毒/艾滋病的疫苗。
Trop Med Int Health. 2000 Jul;5(7):A16-21. doi: 10.1046/j.1365-3156.2000.00593.x.
引用本文的文献
1
Navigating the Complexities of HIV Vaccine Development: Lessons from the Mosaico Trial and Next-Generation Development Strategies.应对HIV疫苗研发的复杂性：马赛克试验的经验教训与下一代研发策略
Vaccines (Basel). 2025 Mar 5;13(3):274. doi: 10.3390/vaccines13030274.
2
Advanced Therapies for Human Immunodeficiency Virus.人类免疫缺陷病毒的先进治疗方法。
Med Sci (Basel). 2024 Jul 18;12(3):33. doi: 10.3390/medsci12030033.
3
Stabilized trimeric peptide immunogens of the complete HIV-1 gp41 N-heptad repeat and their use as HIV-1 vaccine candidates.HIV-1 gp41 N-端七肽重复区三聚体稳定化肽免疫原及其作为 HIV-1 疫苗候选物的用途。
Proc Natl Acad Sci U S A. 2024 May 28;121(22):e2317230121. doi: 10.1073/pnas.2317230121. Epub 2024 May 20.
4
Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans.人体中疫苗诱导的异源 HIV-1 中和抗体 B 细胞谱系。
Cell. 2024 Jun 6;187(12):2919-2934.e20. doi: 10.1016/j.cell.2024.04.033. Epub 2024 May 17.
5
Host cell restriction factors of equine infectious anemia virus.马传染性贫血病毒的宿主细胞限制因子。
Virol Sin. 2023 Aug;38(4):485-496. doi: 10.1016/j.virs.2023.07.001. Epub 2023 Jul 5.
本文引用的文献
1
Low protease activity in B cell follicles promotes retention of intact antigens after immunization.B 细胞滤泡中蛋白酶活性低可促进免疫后完整抗原的保留。
Science. 2023 Jan 27;379(6630):eabn8934. doi: 10.1126/science.abn8934.
2
Vaccination induces HIV broadly neutralizing antibody precursors in humans.接种疫苗可在人体内诱导产生 HIV 广谱中和抗体前体。
Science. 2022 Dec 2;378(6623):eadd6502. doi: 10.1126/science.add6502.
3
KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine.卡波西肉瘤相关疱疹病毒（人疱疹病毒8型）疫苗：一种新型抗癌疫苗的前景与潜在问题
NPJ Vaccines. 2022 Sep 20;7(1):108. doi: 10.1038/s41541-022-00535-4.
4
Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses.重新评估 HIV-1 疫苗保护相关因素分析的价值。
J Virol. 2022 Apr 27;96(8):e0003422. doi: 10.1128/jvi.00034-22. Epub 2022 Apr 6.
5
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults.ALVAC-HIV 和双价 C 型 gp120-MF59 疫苗在成年人中的功效。
N Engl J Med. 2021 Mar 25;384(12):1089-1100. doi: 10.1056/NEJMoa2031499.
6
Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV.AAV 长效递送抗 SIV 单克隆抗体。
Front Immunol. 2020 Mar 17;11:449. doi: 10.3389/fimmu.2020.00449. eCollection 2020.
7
A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge.一种减毒活 RhCMV/SIV 疫苗对异源 SIV 攻击显示出长期疗效。
Sci Transl Med. 2019 Jul 17;11(501). doi: 10.1126/scitranslmed.aaw2607.
8
Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial.腺相关病毒载体免疫预防健康成年人中的 HIV：一项 1 期随机对照试验。
Lancet HIV. 2019 Apr;6(4):e230-e239. doi: 10.1016/S2352-3018(19)30003-7. Epub 2019 Mar 15.
9
Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression.腺相关病毒递送抗 HIV 单克隆抗体可实现长期病毒学抑制。
Immunity. 2019 Mar 19;50(3):567-575.e5. doi: 10.1016/j.immuni.2019.02.005. Epub 2019 Mar 5.
10
Vaccine protection against SIVmac239 acquisition.疫苗对 SIVmac239 感染的保护作用。
Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1739-1744. doi: 10.1073/pnas.1814584116. Epub 2019 Jan 14.
Zotero 插件